A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing
- PMID: 34747265
- PMCID: PMC9007840
- DOI: 10.1177/0272989X211049213
A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing
Abstract
Background: Patient surveillance using repeated biomarker measurements presents an opportunity to detect and treat disease progression early. Frequent surveillance testing using biomarkers is recommended and routinely conducted in several diseases, including cancer and diabetes. However, frequent testing involves tradeoffs. Although surveillance tests provide information about current disease status, the complications and costs of frequent tests may not be justified for patients who are at low risk of progression. Predictions based on patients' earlier biomarker values may be used to inform decision making; however, predictions are uncertain, leading to decision uncertainty.
Methods: We propose the Personalized Risk-Adaptive Surveillance (PRAISE) framework, a novel method for embedding predictions into a value-of-information (VOI) framework to account for the cost of uncertainty over time and determine the time point at which collection of biomarker data would be most valuable. The proposed sequential decision-making framework is innovative in that it leverages the patient's longitudinal history, considers individual benefits and harms, and allows for dynamic tailoring of surveillance intervals by considering the uncertainty in current information and estimating the probability that new information may change treatment decisions, as well as the impact of this change on patient outcomes.
Results: When applied to data from cystic fibrosis patients, PRAISE lowers costs by allowing some patients to skip a visit, compared to an "always test" strategy. It does so without compromising expected survival, by recommending less frequent testing among those who are unlikely to be treated at the skipped time point.
Conclusions: A VOI-based approach to patient monitoring is feasible and could be applied to several diseases to develop more cost-effective and personalized strategies for ongoing patient care.
Highlights: In many patient-monitoring settings, the complications and costs of frequent tests are not justified for patients who are at low risk of disease progression. Predictions based on patient history may be used to individualize the timing of patient visits based on evolving risk.We propose Personalized Risk-Adaptive Surveillance (PRAISE), a novel method for personalizing the timing of surveillance testing, where prediction modeling projects the disease trajectory and a value-of-information (VOI)-based pragmatic decision-theoretic framework quantifies patient- and time-specific benefit-harm tradeoffs.A VOI-based approach to patient monitoring could be applied to several diseases to develop more personalized and cost-effective strategies for ongoing patient care.
Keywords: dynamic decision making; dynamic prediction; personalized medicine; value of information.
Figures




Similar articles
-
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575-84. doi: 10.1016/j.zefq.2013.10.020. Epub 2013 Nov 12. Z Evid Fortbild Qual Gesundhwes. 2013. PMID: 24315327 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760. Health Technol Assess. 2021. PMID: 34990339
-
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z. Trials. 2021. PMID: 33419461 Free PMC article.
-
A value of information framework for assessing the trade-offs associated with uncertainty, duration, and cost of chemical toxicity testing.Risk Anal. 2023 Mar;43(3):498-515. doi: 10.1111/risa.13931. Epub 2022 Apr 22. Risk Anal. 2023. PMID: 35460101 Free PMC article.
Cited by
-
Reinforcement learning for individualized lung cancer screening schedules: A nested case-control study.Cancer Med. 2024 Jul;13(13):e7436. doi: 10.1002/cam4.7436. Cancer Med. 2024. PMID: 38949177 Free PMC article.
-
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission.JCO Clin Cancer Inform. 2025 Jul;9:e2500003. doi: 10.1200/CCI-25-00003. Epub 2025 Jul 7. JCO Clin Cancer Inform. 2025. PMID: 40623281
References
-
- National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. Version 2 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed September 28, 2016.
-
- National Comprehensive Cancer Network. Clinical practice guidelines in oncology: rectal cancer. Version 2 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed September 28, 2016.
-
- Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, and Benson III AB (2013). Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer. American Society of Clinical Oncology Clinical Practice Guideline Endorsement; 31(35): 4465–4470. DOI:10.1200/JCO.2013.50.7442 - DOI - PubMed
-
- El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, Cannady RS, Wong SL, Rose J, Barbour AL, Stein KD, Sharpe KB, Brooks DD, Cowens-Alvarado RL (2015). American Cancer Society Colorectal Cancer Survivorship Care Guidelines. CA Cancer Journal for Clinicians; 65: 427–455. DOI:10.3322/caac.21286 - DOI - PMC - PubMed
-
- National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: prostate cancer. Version 1 2015. Available from: http://www.nccn.org./professionals/physician_gls/pdf/prostate.pdf. Accessed September 28, 2016.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical